Oncology · 2026
Weight Variations during First-Line Systemic Treatment of Metastatic Non-Small Cell Lung Cancer: New Paradigms from Real-World Data.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gravian Alexandre, Pagès Arnaud, Tarabay Anthony, Delaye Virginie, Scottée Florian, Merad Mansouria, Antoun Sami
Аннотация
INTRODUCTION: In studies, weight loss is strongly associated with outcomes in metastatic non-squamous cell lung cancer (mNSCLC). This work examines weight variations in first-line treatment, exploring their mechanisms based on treatment type, age, sex, weight loss, and excess weight before treatment.
METHODS: A retrospective analysis was conducted on patients undergoing first-line treatment. Weight was recorded at four points: before treatment (Wbe), day 1 of treatment (Wd1), 3 months into immune checkpoint inhibitors (ICIs) treatment or maintenance (W3mo), and at progression diagnosis (Wpro).
RESULTS: Among patients (n = 198), 47% received chemotherapy (CT) with ICIs, 26% CT alone, and 27% ICIs alone. At Wd1, 32% were overweight/obese (body mass index kg/m2) (BMI ≥ 25). Weight loss ≥ 5% before treatment was observed in 37%. Mean (SD) weight variations between Wd1 and W3mo were -1.1% (4.6) (CT), -0.2% (7.1) (CT+ICIs), and +0.4% (7.7) (ICIs alone) (p = 0.52). Patients older than 70 compared to ≤70 lost more weight between Wd1 and Wpro (-4.7% vs. -0.4%) (p = 0.019). Patients with pre-treatment weight loss ≥ 5% compared to those without weight loss stabilized or gained weight during treatment (+2.1% vs. -1.5%) (p = 0.009). Patients with BMI ≥ 25 lost more weight during treatment than those with BMI <25 (-1.4% vs. +0.8%) (p = 0.024).
CONCLUSION: Weight variations did not differ significantly across treatment types. Older patients are nutritionally more vulnerable. Pre-treatment significant weight loss ≥ 5% patients stabilized or gained weight during treatment, unlike those without initial weight loss. Pre-treatment weight loss in first-line mNSCLC supports, rather than contraindicates, cancer therapy. Higher BMI was associated with greater weight loss during treatment.
METHODS: A retrospective analysis was conducted on patients undergoing first-line treatment. Weight was recorded at four points: before treatment (Wbe), day 1 of treatment (Wd1), 3 months into immune checkpoint inhibitors (ICIs) treatment or maintenance (W3mo), and at progression diagnosis (Wpro).
RESULTS: Among patients (n = 198), 47% received chemotherapy (CT) with ICIs, 26% CT alone, and 27% ICIs alone. At Wd1, 32% were overweight/obese (body mass index kg/m2) (BMI ≥ 25). Weight loss ≥ 5% before treatment was observed in 37%. Mean (SD) weight variations between Wd1 and W3mo were -1.1% (4.6) (CT), -0.2% (7.1) (CT+ICIs), and +0.4% (7.7) (ICIs alone) (p = 0.52). Patients older than 70 compared to ≤70 lost more weight between Wd1 and Wpro (-4.7% vs. -0.4%) (p = 0.019). Patients with pre-treatment weight loss ≥ 5% compared to those without weight loss stabilized or gained weight during treatment (+2.1% vs. -1.5%) (p = 0.009). Patients with BMI ≥ 25 lost more weight during treatment than those with BMI <25 (-1.4% vs. +0.8%) (p = 0.024).
CONCLUSION: Weight variations did not differ significantly across treatment types. Older patients are nutritionally more vulnerable. Pre-treatment significant weight loss ≥ 5% patients stabilized or gained weight during treatment, unlike those without initial weight loss. Pre-treatment weight loss in first-line mNSCLC supports, rather than contraindicates, cancer therapy. Higher BMI was associated with greater weight loss during treatment.